ABI
REGN icon

Adamant Biomedical Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Adamant Biomedical Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$8.62M Buy
21,000
+3,000
+17% +$1.18M 2.06% 12
2014
Q3 		$6.49M Buy
+18,000
New +$6.03M 1.62% 19

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adamant Biomedical Investments's REGN Position: Q4 2014 in Review

Adamant Biomedical Investments increased its Regeneron Pharmaceuticals (REGN) stake by 17% in Q4 2014, buying an estimated $1.18M and bringing the position to 21,000 shares worth $8.62M. The position accounts for 2.06% of the portfolio, ranked #12.

Adamant Biomedical Investments first reported a position in REGN in Q3 2014 and has held it in 2 quarters since. 511 funds tracked by Wall St. Rank hold REGN as of Q4 2014.

  • Adamant Biomedical Investments held 21,000 shares of Regeneron Pharmaceuticals worth $8.62M as of Q4 2014.
  • Adamant Biomedical Investments bought 3,000 Regeneron Pharmaceuticals shares in Q4 2014, an estimated $1.18M.
  • Regeneron Pharmaceuticals made up 2.06% of Adamant Biomedical Investments's portfolio in Q4 2014, its #12 holding.
  • Adamant Biomedical Investments first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 511 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.